The Biochemistry and Molecular Biology program at Jilin University was established in 1953. It became one of the first Master’s degree-awarding units in China in 1978, obtained doctoral degree conferral rights in 1986, established a Postdoctoral Research Station in 1991, and was recognized as a Key Laboratory of Jilin Province in 1995. In 1996, Professor Wang Liying founded the Molecular Biology Teaching and Research department, pioneering a national-leading research team in genetic engineering vaccines. The team later went on to establish Jilin Province’s first Zebrafish Genetic Engineering Laboratory, as well as the Jilin Provincial Aquatic Laboratory Animal Cross-Regional Collaborative Technology Innovation Center. The current team consists of 4 professors, 2 associate professors, and 1 lecturer, forming a high-quality, dynamic, and collaborative teaching and research collective.

        Teaching achievements: the teaching team is responsible for molecular biology theory and experiment for undergraduate students, Master's and PhD candidates, as well as international students at the School of Basic Medical Sciences international students at the School of Basic Medical Sciences.  They currently owned 2 provincial-level high quality courses. In recent years, the team led more than 20 teaching research projects, published over 20 teaching research papers, and contributed to the compilation of more than ten nationally planned medical textbooks.

        Over the past five years, the team has led key R&D projects from the Ministry of Science and Technology, the National Natural Science Foundation of China, Jilin Provincial Department of Science and Technology, as well as numerous multiple company-sponsored projects, with total funding exceeding ¥15 million. Their work has gained considerable academic influence both domestically and internationally.

        Notable achievements include a recombinant breast cancer vaccine approved by the National Medical Products Administration as a phase I clinical trials drug, and a series of self-designed CpG ODNs in the area of viral infection and immune regulation, which have led to nearly 20 patent applications (5 granted in China, 1 in the U.S.). Some of these CpG ODNs are being used in enhanced hepatitis B vaccine development, with one advancing to Phase I clinical trials in the U.S. The team has published more than 200 papers in top international journals, covering fields such as Genetic engineering vaccines, Autoimmunity, Immunopathological diseases, Prostate cancer, and Genetically Engineered zebrafish.

        The teaching and research team has cultivated over 100 PhD and Master's graduates. Eighty percent of PhD graduates have secured faculty positions at domestic universities or continued postdoctoral research at world-famous universities.